These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 29157287)

  • 1. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.
    Brown ZJ; Heinrich B; Steinberg SM; Yu SJ; Greten TF
    J Immunother Cancer; 2017 Nov; 5(1):93. PubMed ID: 29157287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019.
    Tovoli F; Casadei-Gardini A; Benevento F; Piscaglia F
    Dig Liver Dis; 2019 Aug; 51(8):1067-1073. PubMed ID: 31208929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Nishida N; Kudo M
    Dig Dis; 2017; 35(6):618-622. PubMed ID: 29040995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.
    Elias R; Morales J; Presley C
    Curr Oncol Rep; 2017 Sep; 19(9):62. PubMed ID: 28755314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer.
    Taghizadeh H; Prager GW
    Curr Cancer Drug Targets; 2022 Aug; 22(8):639-650. PubMed ID: 35168521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.
    Schwarz M; Kocher F; Niedersuess-Beke D; Rudzki J; Hochmair M; Widmann G; Hilbe W; Pircher A
    Clin Lung Cancer; 2019 May; 20(3):e247-e250. PubMed ID: 30635258
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
    Helissey C; Champiat S; Soria JC
    Curr Opin Oncol; 2015 Mar; 27(2):108-17. PubMed ID: 25602683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome.
    Afra F; Mahboobipour AA; Salehi Farid A; Ala M
    Biomed Pharmacother; 2023 Sep; 165():115104. PubMed ID: 37393866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
    Rizzo A; Ricci AD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):415-423. PubMed ID: 34429006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.
    Birnbaum MR; Ma MW; Casey MA; Amin BD; Jacobson M; Cheng H; McLellan BN
    J Drugs Dermatol; 2017 Oct; 16(10):1047-1049. PubMed ID: 29036261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
    Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
    Lee CK; Man J; Lord S; Links M; Gebski V; Mok T; Yang JC
    J Thorac Oncol; 2017 Feb; 12(2):403-407. PubMed ID: 27765535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.